Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
RNLX - Renalytix AI Plc
$25.65
1.35(5.56%)9:00:01 PM 1/22/2021
Renalytix AI plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, and systems to generate a unique patient risk score. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company was founded in 2018 and is based in Cardiff, the United Kingdom.
Stock Chart

Summary:

  • A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
  • RSI is at a high level of 86. A high level of RSI indicates the stock is overbought.
  • MACD is crossing MACD signal line at 0.8. MACD crossing signal line is bullish signal.

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics

Stock news

    01/13/2021RNLX
    Renalytix Commends HHS/CMS on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics

    Creates Pathway for Beneficiary Access to KidneyIntelX for Medicare Beneficiary Kidney Disease PopulationsNEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- The Centers for Medicaid & Medicare (CMS) announced the establishment of the Medicare Coverage of Innovative Technology (MCIT) pathway (RIN: 0938-AT88), to provide a coverage pathway for Medicare beneficiaries nationwide to have faster access to new, innovative medical devices and diagnostic tests designated under the Breakthrough Device review pro...

    01/6/2021RNLX
    Renalytix AI (RNLX) Catches Eye: Stock Jumps 7%

    Renalytix AI (RNLX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

    01/6/2021RNLX
    The Daily Biotech Pulse: Aerpio Reviews Strategic Options, Hologic Goes Shopping

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 5) * Curis, Inc. (NASDAQ: CRIS) * Endo International PLC (NASDAQ: ENDP) * Fulgent Genetics Inc (NASDAQ: FLGT) * Genmab 10 Sponsored ADR Ord Shs (NASDAQ: GMAB) * \I-Mab ADR (NASDAQ: IMAB) * Jaguar Health Inc (NASDAQ: JAGX) * Johnson & Johnson (NYSE: JNJ) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Oncorus Inc (NASDAQ: ONCR) * Organogenesis Holdings I...

    01/5/2021RNLX
    Early Risk Identification at Core of Innovative Kidney Care Partnership Between Renalytix, DaVita

    First-of-its-kind program combines early risk assessment of kidney decline and comprehensive care management to help slow kidney disease progression, improve care coordination and reduce costsNEW YORK, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kidney care innovators Renalytix AI (NASDAQ:RNLX, LSE:RENX) and DaVita (NYSE: DVA) are partnering on a program aimed at slowing disease progression and improving health outcomes for the nation’s estimated 37 million adults with chronic kidney disease (CKD). The pr...

    01/4/2021RNLX
    RenalytixAI to Present at the 39th Annual J.P. Morgan Healthcare Conference

    NEW YORK, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today announced the company will be presenting at the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference. RenalytixAI’s management is scheduled to present on Wednesday, January 13 at 10:00 a.m. Eastern Time. ...

    11/29/2020RNLX
    Do Hedge Funds Love Renalytix AI plc (RNLX)?

    In this article you are going to find out whether hedge funds think Renalytix AI plc (NASDAQ:RNLX) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

    11/25/2020RNLX
    Kantaro Receives FDA Emergency Use Authorization for Semi-Quantitative COVID-19 Antibody Test Kit that Detects the Presence and Level of SARS-CoV-2 IgG Antibodies

    Kantaro Biosciences, LLC, a joint venture between the Mount Sinai Health System and RenalytixAI (NASDAQ: RNLX), has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. Unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies and has a broad range of applications in the fight against COVID-19. Through a commercial partnership with Bio-T...

    11/25/2020RNLX
    RenalytixAI Reports Financial Results for First Quarter of Fiscal Year 2021

    NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended September 30, 2020. Recent Highlights * Launched KidneyIntelX within the Mount Sinai Health System * Submitted final package to FDA seeking clearance of KidneyInte...